- Home
- NTIP vs BOLT Comparison
NTIP vs BOLT Comparison
Compare NTIP & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- BOLT
- Stock Information
- Founded
- NTIP 1990
- BOLT 2015
- Country
- NTIP United States
- BOLT United States
- Employees
- NTIP N/A
- BOLT N/A
- Industry
- NTIP Multi-Sector Companies
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- BOLT Health Care
- Exchange
- NTIP Nasdaq
- BOLT Nasdaq
- Market Cap
- NTIP 29.5M
- BOLT 25.3M
- IPO Year
- NTIP 1998
- BOLT 2021
- Fundamental
- Price
- NTIP $1.33
- BOLT $0.57
- Analyst Decision
- NTIP
- BOLT Hold
- Analyst Count
- NTIP 0
- BOLT 5
- Target Price
- NTIP N/A
- BOLT $1.25
- AVG Volume (30 Days)
- NTIP 49.6K
- BOLT 126.9K
- Earning Date
- NTIP 10-24-2024
- BOLT 11-12-2024
- Dividend Yield
- NTIP 7.41%
- BOLT N/A
- EPS Growth
- NTIP N/A
- BOLT N/A
- EPS
- NTIP N/A
- BOLT N/A
- Revenue
- NTIP $1,881,000.00
- BOLT $9,779,000.00
- Revenue This Year
- NTIP N/A
- BOLT $16.30
- Revenue Next Year
- NTIP N/A
- BOLT N/A
- P/E Ratio
- NTIP N/A
- BOLT N/A
- Revenue Growth
- NTIP 129.39
- BOLT 35.86
- 52 Week Low
- NTIP $1.24
- BOLT $0.55
- 52 Week High
- NTIP $2.25
- BOLT $1.56
- Technical
- Relative Strength Index (RSI)
- NTIP 50.04
- BOLT 29.99
- Support Level
- NTIP $1.29
- BOLT $0.63
- Resistance Level
- NTIP $1.34
- BOLT $0.69
- Average True Range (ATR)
- NTIP 0.04
- BOLT 0.03
- MACD
- NTIP 0.01
- BOLT -0.01
- Stochastic Oscillator
- NTIP 76.56
- BOLT 3.49
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.